Today: 8 June 2026
Browse Category

Biotechnology 15 October 2025 - 18 October 2025

MindMed Stock Skyrockets on Psychedelic Breakthroughs – What’s Driving the MNMD Surge?

MindMed Stock Soars 15% to 52-Week High on Psychedelic Breakthrough – What’s Next for MNMD?

MindMed (NASDAQ: MNMD) closed at $13.65 on Oct. 17, up 14.6% in one day and 68% year-to-date, after its LSD-based therapy MM120 showed strong Phase 2b results for Generalized Anxiety Disorder. The FDA granted Breakthrough Therapy status to MM120, with three Phase 3 trials underway. Needham & Co. initiated coverage with a Buy rating and $28 target. MindMed holds $237.9 million in cash, funding operations into 2027.
18 October 2025
··
Gilead Sciences (GILD) Stock Soars on Patent Victory, HIV Breakthroughs, and Analyst Upgrades

Gilead Sciences Stock Soars on Patent Win and HIV Breakthroughs – Will the Rally Continue?

Gilead Sciences stock jumped over 4% on Oct. 17, 2025, closing at $122.81 and hitting a new 52-week high. The surge follows a patent settlement extending exclusivity for Biktarvy until 2036 and FDA approval of Yeztugo, a new HIV prevention shot. Gilead’s market cap stands near $150 billion after a 47% year-to-date gain. Analysts remain bullish but note concerns over U.S. drug pricing pressures.
18 October 2025
···
MindMed Stock Skyrockets on Psychedelic Breakthroughs – What’s Driving the MNMD Surge?

MindMed Stock Skyrockets on Psychedelic Breakthroughs – What’s Driving the MNMD Surge?

MindMed shares hit a 52-week high of $13.09 this week after its LSD-based drug MM120 showed strong Phase 2b results for generalized anxiety disorder and received FDA Breakthrough Therapy designation. The stock is up about 68% year-to-date. Analysts set average price targets near $27.83. MindMed holds $237.9 million in cash, funding operations into 2027.
18 October 2025
··
Gilead Sciences (GILD) Stock Soars on Patent Victory, HIV Breakthroughs, and Analyst Upgrades

Gilead Sciences (GILD) Stock Soars on Patent Victory, HIV Breakthroughs, and Analyst Upgrades

Gilead Sciences shares rose to $123 on October 17, 2025, up nearly 40% from a year ago, lifting its market value to about $150 billion. The company settled U.S. patent litigation over HIV drug Biktarvy, blocking generics until 2036. Its new HIV prevention shot Yeztugo is seeing strong uptake, and Moody’s raised Gilead’s outlook to “Positive.” Gilead also announced a $1.5 billion cell therapy deal with Pregene.
17 October 2025
··
Kezar Life Sciences Stock Soars 40% After FDA Setback Sparks Strategic Shake-Up

Kezar Life Sciences Stock Soars 40% After FDA Setback Sparks Strategic Shake-Up

Kezar Life Sciences said the FDA canceled a key meeting and imposed new trial demands for its lead drug zetomipzomib, delaying development by about two years. The company is now exploring a sale or merger and cutting costs. Shares jumped nearly 40% to $6 on Oct. 17. Kezar reported $90.2 million in cash as of Sept. 30 but faces higher expenses and extended a poison pill plan to 2026.
17 October 2025
··
Achieve Life Sciences Skyrockets on FDA Boost – Is This Nicotine Addiction Breakthrough a Game Changer?

Achieve Life Sciences Skyrockets on FDA Boost – Is This Nicotine Addiction Breakthrough a Game Changer?

Achieve Life Sciences shares jumped over 20% in pre-market trading Friday after receiving an FDA Commissioner’s National Priority Voucher for its lead drug, cytisinicline. The FDA also accepted Achieve’s New Drug Application for cytisinicline as a smoking cessation treatment, with a decision expected by June 2026. ACHV stock reached multi-month highs near $3 following the news. The company’s market cap is about $160 million.
17 October 2025
··
Biotech Breakthrough: GRAIL (GRAL) Stock Surges on New Cancer-Detection Data

GRAIL (GRAL) Rockets to Record High on Samsung Mega-Deal and Cancer Test Breakthrough

GRAL stock surged 14% to a record $86 after Samsung agreed to invest $110 million and help launch GRAIL’s Galleri cancer blood test in Asia. New trial data showed the test doubled early cancer detection rates. GRAIL shares are up over 300% this year, valuing the company at $2.7 billion. Most analysts rate the stock “Hold,” with average targets well below current prices.
17 October 2025
····
Femasys (FEMY) Rockets on Fertility Breakthroughs and FDA Milestones – What’s Behind the Surge?

Femasys (FEMY) Rockets on Fertility Breakthroughs and FDA Milestones – What’s Behind the Surge?

Femasys Inc. shares surged 46% intraday on Oct. 16, 2025, closing up 35% at $0.745 amid heavy trading. The rally followed news of regulatory approvals for its FemBloc® birth control system in Europe, UK, and New Zealand, and a major order from a Spanish distributor. The company also announced new partnerships and showcased its fertility treatments at an industry conference. Femasys remains unprofitable but reported 85% year-over-year sales growth in Q2.
17 October 2025
··
Praxis (PRAX) Stock Skyrockets 180% on Game-Changing Tremor Drug Trial; Analysts See ‘Blockbuster’ Upside

Praxis (PRAX) Stock Skyrockets 180% on Game-Changing Tremor Drug Trial; Analysts See ‘Blockbuster’ Upside

Praxis Precision Medicines shares jumped 180% to $162 on Oct. 16 after its lead drug, ulixacaltamide, met all key endpoints in two Phase 3 trials for essential tremor. The rally added nearly $3 billion to the company’s market cap. Praxis announced a $525 million public offering to fund commercialization and pipeline expansion. Analyst price targets surged, with several now above $250.
17 October 2025
··
GRAIL Inc. Stock Rises on Samsung Partnership and Cancer-Test News

GRAIL Inc. Stock Rises on Samsung Partnership and Cancer-Test News

GRAIL shares jumped 13.6% to close at $85.82 on Oct. 16 after announcing a $110 million equity investment and distribution deal with Samsung C&T and Samsung Electronics. Samsung C&T will exclusively distribute GRAIL’s Galleri cancer test in South Korea, with possible expansion to Japan and Singapore. GRAL’s market cap rose to about $2.7 billion. Most analysts maintain a Hold rating despite the stock’s 321% year-to-date gain.
16 October 2025
···
Moderna’s Wild Ride: Vaccine Hopes Fuel Stock Pop Amid “One-Hit Wonder” Fears

Moderna’s Wild Ride: Vaccine Hopes Fuel Stock Pop Amid “One-Hit Wonder” Fears

Moderna shares rose 5% to $28 but remain down 35% in 2024 and nearly 80% below last year’s level. COVID vaccine sales have collapsed from $18.9 billion in 2022 to $3.1 billion, and Q2 revenue fell 41% to $142 million. The company cut its 2025 revenue forecast and is laying off 10% of staff. Early data from an experimental cancer vaccine showed a 24% tumor response rate in advanced melanoma.
16 October 2025
··
Praxis Precision (PRAX) Stock Skyrockets on Game-Changing Phase 3 Results – What Experts Say

Praxis Precision (PRAX) Stock Skyrockets on Game-Changing Phase 3 Results – What Experts Say

Praxis shares soared nearly 180% premarket Oct. 16 after positive Phase 3 results for ulixacaltamide in essential tremor, hitting a new 52-week high. The drug met all primary and secondary endpoints in two trials and showed no serious safety issues. Praxis plans to seek FDA approval by early 2026. The company reported a Q2 net loss of $71.1M but held $446M in cash at mid-2025.
16 October 2025
··
Sana Biotechnology (SANA) Stock Skyrockets on ‘100-Bagger’ Hype – Experts Debate What’s Next

Sana Biotechnology (SANA) Stock Skyrockets on ‘100-Bagger’ Hype – Experts Debate What’s Next

Sana Biotechnology shares jumped 26% to $5.62 on Oct. 15 after hedge fund manager Eric Jackson called the stock a potential “100-bagger” on X, triggering volatility halts. The rally followed early trial results showing transplanted pancreatic cells produced insulin without immunosuppressive drugs. Sana raised $105 million in summer 2025, extending its cash runway into late 2026. Analyst ratings remain mixed, with targets ranging from $5 to $12.
16 October 2025
··
Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?

Biotech Bombshell: Omeros Stock Skyrockets on $2.1B Novo Nordisk Deal – What’s Next?

Omeros shares soared 150% to $10.42 on Oct. 15 after Novo Nordisk agreed to license its drug zaltenibart (OMS906) for $340 million upfront and up to $2.1 billion in milestones and royalties. Trading volume hit 89.2 million shares, far above average. Omeros reported a Q2 net loss of $25.4 million and $28.7 million in cash as of June 30. Its lead asset narsoplimab remains under FDA and EMA review.
16 October 2025
···
Sana Biotech Shares Skyrocket on 100x Hype – What’s Behind the Rally?

Sana Biotech Shares Skyrocket on 100x Hype – What’s Behind the Rally?

Sana Biotechnology shares jumped 26% to $5.62 on Oct. 15 after hedge fund manager Eric Jackson called the stock “the next 100-bagger” on social media. Trading was briefly halted during the surge. The company recently reported positive diabetes cell-therapy trial data and raised $105 million, extending its cash runway into late 2026. Analyst price targets range from $5 to $12, with a consensus near $7.50.
15 October 2025
··
Recursion RXRX Stock Skyrockets: AI Breakthroughs and Big Pharma Deals Ignite Biotech Surge

Recursion RXRX Stock Skyrockets: AI Breakthroughs and Big Pharma Deals Ignite Biotech Surge

Recursion Pharmaceuticals’ stock jumped about 16% to $6.08 on Oct. 8, 2025, after renewed interest in its AI-driven drug discovery platform. The company reported Q2 revenue of $19.2 million and a net loss of $171.9 million, ending the quarter with $534 million in cash. Management cut 20% of staff in mid-2025 to reduce costs. Analyst targets average $6.50, with mixed ratings.
15 October 2025
···
Origin Agritech’s SEED Stock Skyrockets 92% on China Seed Breakthroughs & Trade Buzz

Origin Agritech’s SEED Stock Skyrockets 92% on China Seed Breakthroughs & Trade Buzz

Origin Agritech (NASDAQ: SEED) surged 92% in after-hours trading on Oct. 14, then fell back near $1.43 by Oct. 15. The Beijing agri-tech firm re-entered Northeast China, showcased new hybrid corn seeds, and announced a partnership with Fengtian Seed Industry. CEO Weibin Yan invested $2.4 million in September, with institutions adding $1.48 million. The stock spike followed U.S.-China trade tensions that lifted agriculture shares.
15 October 2025
·
Evaxion (NASDAQ:EVAX) Stock Rockets After AI-Powered Cancer Vaccine Breakthrough

Evaxion (NASDAQ:EVAX) Stock Rockets After AI-Powered Cancer Vaccine Breakthrough

Evaxion shares jumped 25% on Oct 14, closing at $7.84, after Merck exercised its option on the EVX-B3 vaccine, paying $7.5 million upfront with up to $592 million in milestones. Evaxion will present two-year Phase 2 data for its AI-designed melanoma vaccine at ESMO on Oct 17. The company also announced an upgrade to its AI-Immunology platform and maintains a “Strong Buy” rating from analysts.
15 October 2025
···
Arcadia Biosciences Stock Rockets Amid Trade News – What’s Behind RKDA’s Wild Ride?

Arcadia Biosciences Stock Rockets Amid Trade News – What’s Behind RKDA’s Wild Ride?

Arcadia Biosciences (RKDA) stock soared 68% pre-market Oct 15 to $6.22 after President Trump tweeted about ending some cooking-oil trade with China, sparking a sector rally. The company’s Q2 revenue rose 11% to $1.455 million, all from Zola coconut water, but it posted a $4.46 million net loss due to a $4.5 million write-off on a note from Above Food. The planned merger with Roosevelt Resources remains pending.
15 October 2025
···
Genprex (NASDAQ:GNPX) Stock Skyrockets 40% on Lung Cancer Gene Therapy Breakthrough

Genprex (NASDAQ:GNPX) Stock Skyrockets 40% on Lung Cancer Gene Therapy Breakthrough

Genprex shares surged 41% after hours on Oct 14, 2025, to $0.36 following new data on its lead cancer therapy. The stock closed regular trading up 30% at $0.25, with volume spiking to 15 million shares. Market cap reached about $11 million. The company’s REQORSA gene therapy is in Phase 2 trials for lung cancer, with new preclinical data set for release at an upcoming oncology conference.
15 October 2025
···
1 … 14 15 16 17 18

Stock Market Today

  • RTX Corp Price Targets Diverge as Analysts Weigh Growth and Risks
    June 8, 2026, 1:10 AM EDT. RTX Corp (NYSE: RTX) faces mixed analyst price target revisions amid split investment views. Jefferies raised its price target to $220, citing expected 7% annual organic sales growth through 2028 and stronger earnings per share (EPS) forecasts. Melius Research also upgraded the stock. Conversely, UBS, Morgan Stanley, Citi, and Erste Group trimmed targets or downgraded coverage, reflecting caution amid tariff challenges and geopolitical uncertainties. RTX reported a 21% rise in first-quarter 2026 adjusted EPS at $1.78 and raised its full-year EPS guidance amid $22.08 billion revenue. Raytheon secured key defense contracts, while Collins Aerospace and Pratt & Whitney expanded production capacities in Poland. Despite a stable fair value estimate at $215.27, investors remain watchful of tariff exposure, jet engine costs, and defense demand shifts impacting valuation.

Latest articles

Snap Drops 5%—Ad Recovery Eyed Next

Snap Drops 5%—Ad Recovery Eyed Next

8 June 2026
Snap closed Friday at $5.76, down 5.11% amid a broad tech selloff triggered by a strong jobs report and renewed rate-hike worries, but still ended the week up 0.9%. Investors now await U.S. inflation data and CEO Evan Spiegel’s June 16 AWE keynote on Specs, as Snap faces pressure from weak North American ad revenue, tough competition, and activist demands for cost cuts.
Navitas’ Nvidia-Led Rally Stalls, Eyes on AI Trade Next Week

Navitas’ Nvidia-Led Rally Stalls, Eyes on AI Trade Next Week

8 June 2026
Navitas plunged $5.61 to $25.08 Friday as a $1.3 trillion chip selloff erased Nvidia-driven gains, despite news it issued 3.28 million shares for merger earn-outs and showcased its GaNFast power board at Nvidia’s AI MGX event; investors now face risks from share dilution, sector volatility, and Navitas’s early-stage pivot to high-power AI markets amid ongoing operating losses.
NIO Stock Drops Even as Deliveries Jump, Focus Turns to June Numbers

NIO Stock Drops Even as Deliveries Jump, Focus Turns to June Numbers

8 June 2026
NIO’s U.S.-listed shares plunged 5.8% Friday, erasing a delivery-led rally, as investors focus on whether June sales can hit the company’s Q2 target after May deliveries rose 62.3% to 37,705. NIO needs 42,939–47,939 June deliveries to meet guidance, with risks from China’s saturated car market and recent price pressure.
HPE Stock Faces AI Rally Test With Monday In Focus

HPE Stock Faces AI Rally Test With Monday In Focus

8 June 2026
Hewlett Packard Enterprise plunged 8.36% Friday to $49.20, capping a three-day slide and erasing gains after a post-earnings surge, even as it raised its fiscal 2026 revenue growth outlook to 29%-33% and boosted non-GAAP EPS guidance, with analysts warning that rapid gains may have priced in too much hope too quickly.
Go toTop